Hu Panjie, Chen Huale, Qian Changrui, Fu Qingxia, Zhang Shihang, Huang Zeyu, Liu Haifeng, Zhou Cui, Shen Mo, Zhou Tieli
Department of Clinical Laboratory, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, People's Republic of China.
Key Laboratory of Clinical Laboratory Diagnosis and Translational Research of Zhejiang Province, Wenzhou, Zhejiang, People's Republic of China.
Int J Nanomedicine. 2025 Aug 25;20:10255-10277. doi: 10.2147/IJN.S532807. eCollection 2025.
The global emergence and spread of carbapenem-resistant (CRE) represent a major threat to effective clinical antimicrobial therapy, highlighting the urgent demand for alternative treatment strategies. This study aims to develop dichlorophen-functionalized gold nanoparticles (DDM_Au NPs) as a novel approach to combat CRE and their associated biofilms.
Two structurally related antiparasitic compounds, bithionol and dichlorophen, were functionalized with Au NPs using a one-pot synthesis technique and thoroughly characterized. Their antibacterial activity was assessed through standard antimicrobial susceptibility testing and bacterial growth curve analysis. Antibiofilm properties were evaluated using crystal violet staining, scanning electron microscopy, and confocal laser scanning microscopy. The underlying mechanism of action was investigated by measuring reactive oxygen species production and assessing bacterial membrane permeability. Biocompatibility was evaluated via hemolysis assays, in vivo murine studies, and infection models. A urinary catheter model contaminated with biofilms, along with murine models of abdominal and pulmonary infection, was employed to assess device-associated applicability and therapeutic efficacy in vivo.
DDM_Au NPs demonstrated potent antibacterial activity against CRE, with minimum inhibitory concentrations ranging from 4 to 16 μg/mL. These nanoparticles effectively inhibited biofilm formation and promoted the disruption of mature biofilms, resulting in bacterial load reductions of 2-6 log CFU/mL on infected urinary catheters. Mechanistic studies revealed that their antimicrobial activity was primarily driven by disruption of bacterial membrane integrity and induction of intracellular oxidative stress through elevated reactive oxygen species production. Notably, DDM_Au NPs exhibited favorable biocompatibility and significantly reduced bacterial burdens at infection sites by 4-5 log CFU/mL, while also alleviating inflammatory responses and limiting tissue damage across multiple animal infection models.
This study introduces a streamlined and effective strategy for achieving both antibacterial and antibiofilm effects using antiparasitic drug-functionalized Au NPs. DDM_Au NPs show strong promise as innovative antimicrobial agents for treating clinical CRE infections and reducing environmental contamination in healthcare environments.
耐碳青霉烯类肠杆菌科细菌(CRE)在全球的出现和传播对有效的临床抗菌治疗构成了重大威胁,凸显了对替代治疗策略的迫切需求。本研究旨在开发二氯酚功能化金纳米颗粒(DDM_Au NPs)作为对抗CRE及其相关生物膜的新方法。
使用一锅合成技术将两种结构相关的抗寄生虫化合物硫双二氯酚和二氯酚与金纳米颗粒功能化,并进行全面表征。通过标准抗菌药敏试验和细菌生长曲线分析评估其抗菌活性。使用结晶紫染色、扫描电子显微镜和共聚焦激光扫描显微镜评估抗生物膜特性。通过测量活性氧生成和评估细菌膜通透性来研究其潜在作用机制。通过溶血试验、体内小鼠研究和感染模型评估生物相容性。使用受生物膜污染的导尿管模型以及腹部和肺部感染的小鼠模型来评估体内与器械相关的适用性和治疗效果。
DDM_Au NPs对CRE表现出强大的抗菌活性,最低抑菌浓度范围为4至16μg/mL。这些纳米颗粒有效抑制生物膜形成并促进成熟生物膜的破坏,使感染导尿管上的细菌载量降低2 - 6 log CFU/mL。机制研究表明,它们的抗菌活性主要由细菌膜完整性的破坏和通过增加活性氧生成诱导细胞内氧化应激驱动。值得注意的是,DDM_Au NPs表现出良好的生物相容性,在多个动物感染模型中,感染部位的细菌负荷显著降低4 - 5 log CFU/mL,同时还减轻了炎症反应并限制了组织损伤。
本研究引入了一种使用抗寄生虫药物功能化金纳米颗粒实现抗菌和抗生物膜效果的简化有效策略。DDM_Au NPs作为治疗临床CRE感染和减少医疗环境中环境污染的创新抗菌剂具有很大的前景。